University of Crete (UOC)
Μελέτη του μεταβολισμού της καρνιτίνης και αλλαγές του ενδιάμεσου μεταβολισμού σε κακοήθη νοσήματα παιδιών
Abstract
dc:descriptionIntroduction: Insufficiency or deficiency of carnitine has been found in a number of physiological and pathological situations. Individual studies in cancer patients showed a secondary carnitine deficiency, which may be the result of metabolic changes arising directly or indirectly from chemotherapy or from the actual process of the tumor itself. A decrease in oxidation of fat is expected when deficiency of carnitine occurs. Consequently beta-oxidation is reduced and as result glycolysis increases, favoring the growth of tumor cells, which draw energy from glycolysis. Aim: This thesis was designed to study the alterations of carnitine and its fractions in children with acute leukemia, the probability of insufficiency of carnitine which could arise in these patients, the degree and duration of this insufficiency as their impact in the clinic process and final outcomes of patients. Patients’ characteristics such as age and sex, somatometric features, peripheral blood parameters, serum biochemistry and risk groups for the disease were also examined. Comparison with healthy controls from the same geographical area was also performed. Patients and methods The study population included forty children and adolescents (12 females and 28 males) diagnosed with acute leukemia in the Pediatric Hematology/Oncology Department of our Hospital. The patients received treatment according the BFM-ALL and AML protocols. Thirty seven patients were diagnosed with ALL (Acute Lymphoblastic Leukemia) and three patients with AML (Acute Myelogenous Leukemia). Serum samples and somatometric parameters were examined in four different phases of the disease: Phase A: at the diagnosis, phase B: one year after initiation of chemotherapy, phase C: at the end of therapy and phase D: months to years following completion of therapy. The SPSS 15.0 software package was used for the calculations. P < 0.05 was considered as statistically significant. Results The mean values of acylcarnitines, free carnitine, total carnitine, and ratio acyl/free per phase for patients and contol group appears in table 1. Comparison between all phases was performed regarding the values of Carnitine free, total and ratio acyl /free. Statistically significant decline in values of carnitine free and total has been observed between phase A and phase B (P=0.023) and (P=0.023) respectively. Statistically significant changes also were observed between the phase B and D for both free (P=0.054) and total carnitine (P= 0.035). Between the other phases statistically significant changes were not observed. The ratio acyl/free was not statistically significant changed between the phases. Statistically significant correlations were found between the alanine and lactate in phase A (P = 0.000), phase C (P = 0.009) and phase D (P = 0.000). A statistically significant correlation between the alanine and lactate with free fatty acids was observed only in phase D (P = 0.001 and P = 0.000) respectively. Conclusions: In the present study insufficiency of carnitine was not observed although a statistically significant decrease in carnitine levels was found within different phases of the disease especially during induction and consolidation treatment (phase A-B) for both free & total carnitine (p=0.023). The decrease in carnitine levels free and total was transient and was reversed after the end of chemotherapy p= 0.054 and 0.035 respectively. The abatement found is not correlated with nutritional status, age, gender, risk group of the disease, or hemoglobin levels. Patients with higher BMI z-score after the first year of treatment tend to have a better disease course and prognosis. Long term follow up of these patients may allow a more precise correlation of the decrease in levels of carnitine found in our study with late effects of leukemia and chemotherapy. Further studies may elucidate the impact of this decrease in carnitine’s levels in prognosis and final outcome of the disease as well as the potential benefit from supplementation of carnitine during chemotherapy.
Degree
thesis:*- Grantor dc:publisher
- University of Crete (UOC)
- Year dc:date
- 2011
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Ρογαλίδου, Μαρία
- Rogalidou, Maria
Subjects
dc:subject × 16Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/28598